HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Finkel, S. I. Articles by Batzar, E. Search for Related Content PubMed PubMed Citation Articles by Finkel, S. I. Articles by Batzar, E.

Comparative Efficacy of Sertraline vs. Fluoxetine in Patients Age 70 or Over With Major Depression

Received February 28, 1998; revised July 5, 1998; accepted September 31, 1998. From Northwestern University Medical School. Drs. Richter and Clary and Mr. Batzar are at Pfizer, Inc. Address correspondence to Dr. Finkel, Suite 550, 303 E. Ohio St., Chicago, IL 60611-3317.

Using data from a larger 12-week clinical trial, the authors evaluated the comparative efficacy and safety of sertraline (n=42) and fluoxetine (n=33) in patients over age 70 with a diagnosis of major depressive disorder. Similar improvement on measures of depression, including remission of depressive symptoms, was evident, although significantly more sertraline-treated patients achieved a criterion clinical response. Significantly greater improvement for the sertraline group was apparent on the Digit Symbol Substitution Test, but not on two other measures of cognitive functioning. Although there was no difference in the rate of adverse events experienced, fluoxetine-treated patients lost significantly more body weight over the 12-week trial than did sertraline-treated patients, whereas the latter group exhibited significantly more "shaking. "

Key Words: Depression • Sertraline • Fluoxetine

This article has been cited by other articles:

				J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF]

				M. B. Keller Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: Remission and Beyond JAMA, June 18, 2003; 289(23): 3152 - 3160. [Abstract] [Full Text] [PDF]

				A. F. Schatzberg, C. Kremer, H. E. Rodrigues, G. M. Murphy Jr., and The Mirtazapine vs. Paroxetine Study Group Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients Am J Geriatr Psychiatry, October 1, 2002; 10(5): 541 - 550. [Abstract] [Full Text] [PDF]

				B. H. Mulsant, B. G. Pollock, R. Nebes, M. D. Miller, R. A. Sweet, J. Stack, P. R. Houck, S. Bensasi, S. Mazumdar, and C. F. Reynolds III A Twelve-Week, Double-Blind, Randomized Comparison of Nortriptyline and Paroxetine in Older Depressed Inpatients and Outpatients Am J Geriatr Psychiatry, November 1, 2001; 9(4): 406 - 414. [Abstract] [Full Text] [PDF]